Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05821725
Other study ID # CRO-2022-09-WH-BZ-ZM
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2023
Est. completion date November 2023

Study information

Verified date August 2023
Source Colgate Palmolive
Contact Marcelo Faveri, DDS, PhD
Phone 551198644-9962
Email mdfaveri@uol.com.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical study aims to investigate the impact of a topical hyaluronic acid (HA) gel on postoperative pain and wound healing at palatal donor sites in patients undergoing mucogingival procedures involving a de-epithelialized gingival graft (DGG) from the palate. The study design is a Phase III, randomized, double-blind, parallel-group, clinical trial, conducted in a single center, with 30 subjects aged 18-70 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 2023
Est. primary completion date November 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Males and females, between 18-70 years of age - Informed Consent Form signed and availability for the duration of the study - Good general health (absence of any condition that, in the opinion of the Principal Investigator, might constitute a risk to the subject while participating in the study - Clinical indication for mucogingival surgery that requires a de-epithelialized gingival graft (DGG) from the palate - Willingness to provide information related to their medical history - Minimum of 10 uncrowned permanent natural teeth (excluding third molars) - Normal salivary flow Exclusion Criteria: - Oral pathology, chronic disease, or a history of allergy to testing products - Subject using anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory medication or daily analgesics within one month prior to the start of the study or scheduled to start such intake during the course of the study - Subject participating in any other clinical study - Subject pregnant or breastfeeding - Subject allergic to oral care products, personal care consumer products, or their ingredients - Extended use of antibiotics or therapeutic mouthwash any time during the three months prior to entry into the study - A medical history reporting that the subject has a current systemic or autoimmune disease, such as diabetes, lupus, etc - Ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Hyaluronic acid
Hyaluronic acid and hemostatic sponge
Control
Hemostatic sponge

Locations

Country Name City State
Brazil Faveri Academy Guarulhos São Paulo

Sponsors (1)

Lead Sponsor Collaborator
Colgate Palmolive

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter Baseline
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter 3 days after surgery
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter 7 days after surgery
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter 14 days after surgery
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter 21 days after surgery
Primary Wound healing area Wound size will be assessed at Baseline after obtaining the graft, and 3, 7, 14, 21, and 42 days after surgery via direct measurement with a Periodontal Probe UNC 15 (Hu-Friedy, United States), length and height of the wound will be measured and recorded to the nearest millimeter 42 days after surgery
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. Baseline
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. 3 days after surgery
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. 7 days after surgery
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. 14 days after surgery
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. 21 days after surgery
Secondary Pain assessment Pain will be assessed via Visual Analog Scale (VAS) at Baseline, 3, 7, 14, 21, and 42 days after surgery. A line of 10 cm will be used in which at the left end of the line will have a verbal anchor stating "No pain" and on the other end the verbal anchor of "The most intense pain that I ever felt". The subjects will place a mark on the line and the distance from the beginning of the line up to the mark will be measured and recorded. 42 days after surgery
See also
  Status Clinical Trial Phase
Completed NCT03713073 - Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site N/A
Completed NCT02239042 - Effect of Low-level Laser Therapy on Palatal Wound Healing Phase 4
Completed NCT03000426 - Photobiomodulation of Palatal Donor Site After Free Gingival Graft Removal N/A
Recruiting NCT03972267 - Influence of Enamel Matrix Derivative (Emdogain®) on Palate Wound Healing. N/A
Completed NCT02580357 - Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds N/A
Recruiting NCT03576339 - Influence of Electrical Stimulation on Palatal Wound Healing. N/A